HOME >> MEDICINE >> NEWS
NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed

Phase III trial in Thailand to determine efficacy will be supported by NIAID through a combined NIAID-DoD Program

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the U.S. Army Medical Research and Materiel Command (USAMRMC) of the Department of Defense (DoD), support a broad, comprehensive HIV/AIDS research and development program. Two recent decisions will substantially contribute to a coordinated and comprehensive U.S. government effort to develop preventive HIV vaccines.

DoD HIV Research and Development Program is transferred to NIH

On January 4, 2002, the White House Office of Management and Budget directed the transfer of oversight and management for the DoD HIV Research and Development Program of USAMRMC to the NIH. NIAID, which has the primary responsibility for HIV/AIDS research within the NIH, will assume responsibility for this program beginning October 1, 2002. Both the NIH and USAMRMC are committed to maintaining and building on the various strengths of each program. The Henry M. Jackson Foundation for the Advancement of Military Medicine, a private, non-profit organization that works closely with the Walter Reed Army Institute for Research (WRAIR), a subordinate laboratory of USAMRMC, will be a resource for both programs.

NIAID and USAMRMC have a common goal: to prevent the further spread of HIV/AIDS by developing safe and effective vaccines, other prevention strategies and innovative HIV treatments. The research activities of both groups are complementary and will be effectively integrated. The major difference between the two is the constituencies they serve: the USAMRMC research program primarily serves young, healthy adults on active military duty who are subject to worldwide deployment, while the NIAID research program serves all civilian age groups and addresses all HIV-associated conditions, such as opportunistic
'"/>

Contact: Gregory Roa
greg.roa@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
25-Feb-2002


Page: 1 2 3 4

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: